Bioequivalence of Ertugliflozin/Sitagliptin Fixed‐Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components

A fixed‐dose combination (FDC) tablet of ertugliflozin, a selective inhibitor of sodium‐glucose cotransporter 2, and sitagliptin, a dipeptidyl peptidase‐4 inhibitor, was developed for the treatment of patients with type 2 diabetes mellitus. Four studies were conducted under fasted conditions to demo...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Clin Pharmacol Drug Dev
Главные авторы: Fediuk, Daryl J., Matschke, Kyle, Liang, Yali, Pelletier, Kathleen B., Wei, Hua, Shi, Haihong, Bass, Almasa, Hickman, Anne, Terra, Steven G., Zhou, Susan, Krishna, Rajesh, Sahasrabudhe, Vaishali
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley and Sons Inc. 2019
Предметы:
Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6851892/
https://ncbi.nlm.nih.gov/pubmed/31219248
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpdd.722
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы